Pyxis Oncology Inc
PYXS
查看详细走势图
1.510USD
-0.030-1.95%
收盘 02/06, 16:00（美东）报价延迟15分钟
93.85M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-1.95%
5天
+4.14%
1月
+6.34%
6月
+41.12%
今年开始到现在
+31.30%
1年
+7.86%
查看详细走势图
TradingKey Pyxis Oncology Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Pyxis Oncology Inc当前公司基本面数据相对稳定，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名113/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价6.42。中期看，股价处于下降通道。近一个月，市场表现较差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Pyxis Oncology Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
Pyxis Oncology Inc亮点
亮点风险
Pyxis Oncology, Inc. is a clinical-stage company focused on developing therapeutics to target difficult-to-treat cancers. The Company is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes micvotobart pelidotin (MICVO), PYX-106, Sotigalimab (PYX-107), PYX-203, PYX-102, and APX601. The Company’s lead product candidate, MICVO, is an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component of the tumor extra-cellular matrix (ECM). MICVO is designed to generate a multi-pronged attack on difficult-to-treat cancers by directly killing cancer cells, reducing ECM density, inhibiting tumor angiogenesis and mobilizing an anti-tumor immune response. The Company’s ADC, MICVO, consists of human Immunoglobulin G1 (IgG1) and is site-specifically conjugated with a cleavable linker and a microtubule inhibitor (optimized auristatin) payload.
业绩增长期
公司处于发展阶段，最新年度总收入16.15M美元
估值合理
公司最新PE估值-0.95，处于3年历史合理位
机构减仓
最新机构持股24.80M股，环比减少30.25%
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值3.51K
分析师目标
根据
9
位分析师
买入
评级
6.425
目标均价
+325.50%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Pyxis Oncology Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Pyxis Oncology Inc简介
Pyxis Oncology, Inc. is a clinical-stage company focused on developing therapeutics to target difficult-to-treat cancers. The Company is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes micvotobart pelidotin (MICVO), PYX-106, Sotigalimab (PYX-107), PYX-203, PYX-102, and APX601. The Company’s lead product candidate, MICVO, is an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component of the tumor extra-cellular matrix (ECM). MICVO is designed to generate a multi-pronged attack on difficult-to-treat cancers by directly killing cancer cells, reducing ECM density, inhibiting tumor angiogenesis and mobilizing an anti-tumor immune response. The Company’s ADC, MICVO, consists of human Immunoglobulin G1 (IgG1) and is site-specifically conjugated with a cleavable linker and a microtubule inhibitor (optimized auristatin) payload.
公司代码PYXS
公司Pyxis Oncology Inc
CEOSullivan (Lara S)
网址https://pyxisoncology.com/
相关品种
